cdk4/6 inhibitors & endocrine therapy: adverse events
Published 5 years ago • 183 plays • Length 4:35Download video MP4
Download video MP3
Similar videos
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer
-
6:46
cdk4/6 inhibitors & endocrine therapy: treatment resistance
-
6:05
cdk4/6 inhibitors & endocrine therapy: selecting a regimen
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
4:15
case 2: choosing a cdk4/6 inhibitor in er breast cancer
-
32:14
navigating between endocrine therapy, chemotherapy, and cdk 4/6 inhibitors for high-risk hr /her2...
-
4:37
case 2: cdk4/6 inhibitors in er breast cancer
-
1:26
ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
-
3:21
benefits and challenges of cdk4/6 inhibitors
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
9:18
clinical experience: cdk4/6 inhibitors in breast cancer
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
17:31
survival analysis of of cdk4/6 inhibitors andendocrine therapy in hr positive,her2 negative day1
-
5:32
esmo 2020 expert video report on cdk4 6i in the adjuvant treatment of breast cancer
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors